HONG KONG (Reuters) – Biotechs without revenue can apply to list in Hong Kong from Monday under new rules aimed at attracting listings, mostly from China’s fast-developing market. The move is part of a bold effort to rival New York’s Nasdaq, the …
( read original story …)